Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
7.28
+0.09 (1.25%)
Aug 12, 2026, 9:55 AM EDT - Market open
Aardvark Therapeutics Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Aardvark Therapeutics stock has a consensus rating of "Buy" and an average price target of $15.78. The average 1-year stock price forecast is 116.76% higher than the current stock price, while the lowest is $4.00 (-45.05%) and the highest is $45 (+518.13%).
Price Target: $15.78 (+116.76%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Aardvark Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 8 | 8 | 6 | 6 | 6 |
| Buy | 2 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Total | 12 | 12 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Sell Reiterates $3 | Sell | Reiterates | $3 | -58.79% | Aug 12, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $6 | Hold | Maintains | $6 | -17.58% | Aug 12, 2026 |
| William Blair | William Blair | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Aug 12, 2026 |
| H.C. Wainwright | H.C. Wainwright | Hold Reiterates $6 | Hold | Reiterates | $6 | -17.58% | Jul 20, 2026 |
| B. Riley Securities | B. Riley Securities | Buy Maintains $8 → $7 | Buy | Maintains | $8 → $7 | -3.85% | May 15, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.67
from -2.93
EPS Next Year
-3.10
from -3.67
EPS and Forward PE are based on non-GAAP adjusted numbers.